Medical News

RSS

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Study links procedural pain and detectable oxidative stress in neonates

There was a time when a belief was widely held that premature neonates did not perceive pain. That, of course, has been refuted but measurements of neonate pain tend to rely on inexact measures, such as alertness and ability to react expressively to pain sensations. Researchers at Loma Linda University reported in The Journal of Pain that there is a significant relationship between procedural pain and detectable oxidative stress in neonates.

2 Jul 2012

Political cartoon: 'Super-Size Hero?'

Kaiser Health News provides a fresh take on health policy developments with "Super-Size Hero?" by Rick McKee.

2 Jul 2012

FDA approves Roche's new HIV viral load test

Roche announced today that a new HIV viral load test has been approved by the United States Food and Drug Administration (FDA) and will be commercially available in the US later this year.

2 Jul 2012

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Fact sheet on U.S. government's global health work in Haiti

The U.S. State Department's Office of the Haiti Special Coordinator last week published a fact sheet on the U.S. government's global health work in Haiti.

2 Jul 2012

Watching 3D movies can lead to visual and motion sickness

Watching 3D movies can "immerse" you in the experience—but can also lead to visual symptoms and even motion sickness, reports a study - "Stereoscopic Viewing and Reported Perceived Immersion and Symptoms", in the July issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

2 Jul 2012

Potential link between mutant huntingtin, cell loss and cell death in Huntington's disease

Using an in vitro cell model of Huntington's disease (HD), researchers at Florida Atlantic University's Charles E. Schmidt College of Medicine have discovered a novel mechanism and potential link between mutant huntingtin, cell loss and cell death or apoptosis in the brain, which is responsible for the devastating effects of this disease. Apoptosis has been proposed as one of the mechanisms leading to neuronal death in HD.

2 Jul 2012

Working to reduce adolescent pregnancy in Zimbabwe

As part of a monthly series of posts guest edited by FHI 360 on behalf of USAID'S Interagency Youth Working Group (IYWG), this post in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog by Primrose Nanchani Manyalo, a field officer at Restless Development, discusses how "adolescent pregnancy is a harsh reality that many young girls encounter."

2 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

Community Health Systems acquires Memorial Health Systems in York

Community Health Systems, Inc. announced today that subsidiaries of the Company have acquired substantially all of the assets of Memorial Health Systems in York, Pennsylvania.

2 Jul 2012

Pediatric pain still common in hospitals

Despite advances in the understanding and treatment of pediatric pain, many hospitalized children continue to experience serious pain, according to a Johns Hopkins Children’s Center study published online ahead of print in the journal Pain Management Nursing.

2 Jul 2012

Transcranial direct current stimulation can enhance outcome of swallowing therapy for post-stroke dysphagia

After stroke, patients often suffer from dysphagia, a swallowing disorder that results in greater healthcare costs and higher rates of complications such as dehydration, malnutrition, and pneumonia.

2 Jul 2012

July issue of WHO Bulletin available online

The July issue of the WHO Bulletin features an editorial on meeting the challenges of women's health beyond reproduction;

2 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

Obesity during adulthood linked to sexual and physical abuse during childhood

Investigators from Boston University School of Medicine (BUSM) and Boston University's Slone Epidemiology Center report research findings that may shed light on influences on obesity during adulthood. Appearing in the journal Pediatrics, the study found an association of severity of sexual and physical abuse during childhood and adolescence with obesity during adulthood.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

ETView receives European pre-market clearance for Viva-EB airway device product family

ETView today announced that the company has received European pre-market clearance for the Viva-EB product family following review of a Technical File submission by Medical Device Certification GmbH ("MDC").

2 Jul 2012